by Admin Neo Lumina | Sep 14, 2023 | News
Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester Leading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine Inc., Jazz...
by Admin Neo Lumina | Sep 7, 2023 | News
Filament Health Announces FDA Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010 The University of Washington and the University of California, Los Angeles have been approved to study PEX010 in clinical trials for mental health...
by Admin Neo Lumina | Sep 7, 2023 | News
New Study Shows Candy-Flipping Can Reduce Bad Trips A new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics. “Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive...
by Admin Neo Lumina | Sep 3, 2023 | News
Eating Disorder Recovery: 12 Tips to Aid in the Process Recovering from an eating disorder can be a long journey. Treatments for eating disorders are complex and multifaceted, but recovery is possible.(1) Because eating disorders can lead to serious medical...
by Admin Neo Lumina | Sep 1, 2023 | News
Otsuka Pharmaceutical agrees to buy Mindset Pharma The acquisition has received approvals from the boards of directors of both companies. Otsuka Pharmaceutical has signed a definitive agreement to acquire drug discovery-based research and development company Mindset...
by Admin Neo Lumina | Aug 28, 2023 | News
Filament Health Enters Exclusive Licensing Agreement With Neolumina Bioscience Inc Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced an exclusive global licensing agreement...
